Minimally-invasive and non-invasive methods of thermal destruction in the treatment of patients with aggressive fibromatosis ; Возможности мини- и неинвазивных методов термической деструкции в лечении больных агрессивным фиброматозом

Authors: L. I. Moskvicheva, Л. И. Москвичева

Source: Siberian journal of oncology; Том 22, № 5 (2023); 96-104 ; Сибирский онкологический журнал; Том 22, № 5 (2023); 96-104 ; 2312-3168 ; 1814-4861

Subject Terms: USgHIFU, aggressive fibromatosis, radiofrequency ablation, microwave ablation, cryodestruction, high-intensity focused ultrasound therapy, HIFU therapy, MRgHIFU, агрессивный фиброматоз, радиочастотная аблация, микроволновая аблация, криодеструкция, высокоинтенсивная фокусированная ультразвуковая терапия, HIFU-терапия

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2764/1161; Martínez Trufero J., Pajares Bernad I., Torres Ramón I., Hernando Cubero J., Pazo Cid R. Desmoid-Type Fibromatosis: Who, When, and How to Treat. Curr Treat Options Oncol. 2017; 18(5): 29. doi:10.1007/s11864-017-0474-0.; Kasper B. The EORTC QLQ-C30 Summary Score as a Prognostic Factor for Survival of Patients with Cancer: A Commentary. Oncologist. 2020; 25(4): 610–1. doi:10.1634/theoncologist.2019-0749.; van Broekhoven D.L., Grünhagen D.J., den Bakker M.A., van Dalen T., Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015; 22(9): 2817–23. doi:10.1245/s10434-015-4632-y.; Li Destri G., Ferraro M.J., Calabrini M., Pennisi M., Magro G. Desmoid-type fibromatosis of the mesentery: report of a sporadic case with emphasis on differential diagnostic problems. Case Rep Med. 2014. doi:10.1155/2014/850180.; Alman B., Attia S., Baumgarten C., et al. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensusbased guideline approach for adult and paediatric patients. Eur J Cancer. 2020; 127: 96–107. https://doi.org/10.1016/j.ejca.2019.11.013.; Koskenvuo L., Ristimäki A., Lepistö A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017; 116(6): 716–21. doi:10.1002/jso.24699.; Sanchez-Mete L., Ferraresi V., Caterino M., Martayan A., Terrenato I., Mannisi E., Stigliano V. Desmoid Tumors Characteristics, Clinical Management, Active Surveillance, and Description of Our FAP Case Series. J Clin Med. 2020; 9(12): 4012. doi:10.3390/jcm9124012.; Crago A.M., Chmielecki J., Rosenberg M., O’Connor R., Byrne C., Wilder F.G., Thorn K., Agius P., Kuk D., Socci N.D., Qin L.X., Meyerson M., Hameed M., Singer S. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015; 54(10): 606–15. doi:10.1002/gcc.22272.; Skubitz K.M. Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor. Mayo Clin Proc. 2017; 92(6): 947–64. doi:10.1016/j.mayocp.2017.02.012.; Kasper B., Baumgarten C., Garcia J., Bonvalot S., Haas R., Haller F., Hohenberger P., Penel N., Messiou C., van der Graaf W.T., Gronchi A.; Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017; 28(10): 2399–408. doi:10.1093/annonc/mdx323.; Penel N., Le Cesne A., Bonvalot S., Giraud A., Bompas E., Rios M., Salas S., Isambert N., Boudou-Rouquette P., Honore C., Italiano A., RayCoquard I., Piperno-Neumann S., Gouin F., Bertucci F., Ryckewaert T., Kurtz J.E., Ducimetiere F., Coindre J.M., Blay J.Y. Surgical versus nonsurgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017; 83: 125–31. doi:10.1016/j.ejca.2017.06.017.; Choi S.H., Yoon H.I., Kim S.H., Kim S.K., Shin K.H., Suh C.O. Optimal radiotherapy strategy for primary or recurrent fibromatosis and long-term results. PLoS One. 2018; 13(5). doi:10.1371/journal.pone.0198134.; Janssen M.L., van Broekhoven D.L., Cates J.M., Bramer W.M., Nuyttens J.J., Gronchi A., Salas S., Bonvalot S., Grünhagen D.J., Verhoef C. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017; 104(4): 347–57. doi:10.1002/bjs.10477.; Bishop A.J., Zarzour M.A., Ratan R., Torres K.E., Feig B.W., Wang W.L., Lazar A.J., Moon B.S., Roland C.L., Guadagnolo B.A. LongTerm Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. Int J Radiat Oncol Biol Phys. 2019; 103(5): 1167–74. doi:10.1016/j.ijrobp.2018.12.012.; Bishop A.J., Landry J.P., Roland C.L., Ratan R., Feig B.W., Moon B.S., Zarzour M.A., Wang W.L., Lazar A.J., Lewis V.O., Torres K.E., Guadagnolo B.A. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020; 126(14): 3265–73. doi:10.1002/cncr.32921.; Gronchi A., Colombo C., Le Péchoux C., Dei Tos A.P., Le Cesne A., Marrari A., Penel N., Grignani G., Blay J.Y., Casali P.G., Stoeckle E., Gherlinzoni F., Meeus P., Mussi C., Gouin F., Duffaud F., Fiore M., Bonvalot S.; ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014; 25(3): 578–83. doi:10.1093/annonc/mdt485.; Болотина Л.В., Новикова О.В., Прокофьева Е.А. Роль химиотерапии в лечении агрессивного фиброматоза. Онкология. Журнал им. П.А. Герцена. 2012; 1(3): 72–6.; Palassini E., Frezza A.M., Mariani L., Lalli L., Colombo C., Fiore M., Messina A., Casale A., Morosi C., Collini P., Stacchiotti S., Casali P.G., Gronchi A. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Cancer J. 2017; 23(2): 86–91. doi:10.1097/PPO.0000000000000254.; Toulmonde M., Pulido M., Ray-Coquard I., Andre T., Isambert N., Chevreau C., Penel N., Bompas E., Saada E., Bertucci F., Lebbe C., Le Cesne A., Soulie P., Piperno-Neumann S., Sweet S., Cecchi F., Hembrough T., Bellera C., Kind M., Crombe A., Lucchesi C., Le Loarer F., Blay J.Y., Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019; 20(9): 1263–72. doi:10.1016/S14702045(19)30276-1.; Kummar S., O’Sullivan Coyne G., Do K.T., Turkbey B., Meltzer P.S., Polley E., Choyke P.L., Meehan R., Vilimas R., Horneffer Y., Juwara L., Lih A., Choudhary A., Mitchell S.A., Helman L.J., Doroshow J.H., Chen A.P. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017; 35(14): 1561–9. doi:10.1200/JCO.2016.71.1994.; Gounder M.M., Mahoney M.R., Van Tine B.A., Ravi V., Attia S., Deshpande H.A., Gupta A.A., Milhem M.M., Conry R.M., Movva S., Pishvaian M.J., Riedel R.F., Sabagh T., Tap W.D., Horvat N., Basch E., Schwartz L.H., Maki R.G., Agaram N.P., Lefkowitz R.A., Mazaheri Y., Yamashita R., Wright J.J., Dueck A.C., Schwartz G.K. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018; 379(25): 2417–28. doi:10.1056/NEJMoa1805052.; Testa S., Bui N.Q., Charville G.W., Avedian R.S., Steffner R., Ghanouni P., Mohler D.G., Ganjoo K.N. Management of Patients with Newly Diagnosed Desmoid Tumors in a First-Line Setting. Cancers (Basel). 2022; 14(16): 3907. doi:10.3390/cancers14163907.; Mikhael R., Smith M., Tzanis D., Watson S., Miah A.B., Bonvalot S. Desmoid tumors: who, when and how to treat? Curr Opin Oncol. 2022; 34(4): 335–41. doi:10.1097/CCO.0000000000000854.; Zhou M.Y., Bui N.Q., Charville G.W., Ghanouni P., Ganjoo K.N. Current management and recent progress in desmoid tumors. Cancer Treat Res Commun. 2022; 31. doi:10.1016/j.ctarc.2022.100562.; Москвичева Л.И., Сидоров Д.В., Ложкин М.В., Петров Л.О., Забелин М.В. Современные методы абляции злокачественных новообразований печени. Research and Practical Medicine Journal. 2018; 5(4): 58–71. doi:10.17709/2409-2231-2018-5-4-6.; Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местнораспространенном раке поджелудочной железы. Research and Practical Medicine Journal. 2018; 5(2): 86–99. doi:10.17709/24092231-2018-5-2-10.; Hinshaw J.L., Lubner M.G., Ziemlewicz T.J., Lee F.T., Brace C.L. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation – what should you use and why? Radiographics. 2014; 34(5): 1344–62. doi:10.1148/rg.345140054.; Zhang Z., Shi J., Yang T., Liu T., Zhang K. Management of aggressive fibromatosis. Oncol Lett. 2021; 21(1): 43. doi:10.3892/ol.2020.12304.; Tsz-Kan T., Man-Kwong C., Shu Shang-Jen J., Ying-Lee L., Wai Man-Wah A., Hon-Shing F. Radiofrequency ablation of recurrent fibromatosis. J Vasc Interv Radiol. 2007; 18(1 Pt 1): 147–50. doi:10.1016/j.jvir.2006.08.001.; Ilaslan H., Schils J., Joyce M., Marks K., Sundaram M. Radiofrequency ablation: another treatment option for local control of desmoid tumors. Skeletal Radiol. 2010; 39(2): 169–73. doi:10.1007/s00256-009-0807-6.; Barrow E., Newton K., Rajashanker B., Lee S., Evans D.G., Hill J. Successful radiofrequency ablation of an anterior abdominal wall desmoid in familial adenomatous polyposis. Colorectal Dis. 2013; 15(3): 160–3. doi:10.1111/codi.12064.; Wang L., Xu D., Chen L., Huang P. Percutaneous ultrasound-guided radiofrequency ablation for giant desmoid tumors of the intra-abdominal cavity in a patient with Gardner syndrome. J Cancer Res Ther. 2021; 17: 1286–8. doi:10.4103/jCRT.jCRT_316_21.; Cobianchi L., Ravetta V., Viera F.T., Filisetti C., Siri B., Segalini E., Maestri M., Dominioni T., Alessiani M., Rossi S., Dionigi P. The challenge of extraabdominal desmoid tumour management in patients with Gardner’s syndrome: radiofrequency ablation, a promising option. World J Surg Oncol. 2014; 12: 361. doi:10.1186/1477-7819-12-361.; Lubner M.G., Brace C.L., Hinshaw J.L., Lee F.T. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010; 21 (8s): 192–203. doi:10.1016/j.jvir.2010.04.007.; Facciorusso A., Di Maso M., Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 2016; 32(3): 339–44. doi:10.3109/02656736.2015.1127434.; Sun Y., Cheng Z., Dong L., Zhang G., Wang Y., Liang P. Comparison of temperature curve and ablation zone between 915- and 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine livers. Eur J Radiol. 2012; 81(3): 553–7. doi:10.1016/j.ejrad.2011.02.013.; Yu N.C., Lu D.S., Raman S.S., Dupuy D.E., Simon C.J., Lassman C., Aswad B.I., Ianniti D., Busuttil R.W. Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters--pilot comparison with pathologic findings. Radiology. 2006; 239(1): 269–75. doi:10.1148/radiol.2383041592.; Sainani N.I., Gervais D.A., Mueller P.R., Arellano R.S. Imaging after percutaneous radiofrequency ablation of hepatic tumors: Part 1, Normal findings. Am J Roentgenol. 2013; 200(1): 184–93. doi:10.2214/AJR.12.8478.; Vogl T.J., Nour-Eldin N.A., Hammerstingl R.M., Panahi B., Naguib N.N.N. Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms – Review Article. Rofo. 2017; 189(11): 1055–66. doi:10.1055/s-0043-117410.; Martínez-Martínez A., García-Espinosa J., Láinez Ramos-Bossini A.J., Ruiz Santiago F. Percutaneous Microwave Ablation of Desmoid Fibromatosis. Korean J Radiol. 2021; 22(6): 944–50. doi:10.3348/kjr.2020.0768.; Goldberg D., Woodhead G., Hannallah J., Young S. Role of the Interventional Radiologist in the Treatment of Desmoid Tumors. Life (Basel). 2023; 13(3): 645. https://doi.org/10.3390/life13030645.; Hoffmann N.E., Bischof J.C. The cryobiology of cryosurgical injury. Urology. 2002; 60(2s1): 40–9. doi:10.1016/s0090-4295(02)01683-7.; Gage A.A., Guest K., Montes M., Caruana J.A., Whalen D.A. Effect of varying freezing and thawing rates in experimental cryosurgery. Cryobiology. 1985; 22(2): 175–82. doi:10.1016/0011-2240(85)90172-5.; Mahnken A.H., König A.M., Figiel J.H. Current Technique and Application of Percutaneous Cryotherapy. Rofo. 2018; 190(9): 836–46. doi:10.1055/a-0598-5134.; Seifert J.K., Morris D.L. World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999; 23(2): 109–13; discussion 113–4. doi:10.1007/pl00013173.; Vora B.M.K., Munk P.L., Somasundaram N., Ouellette H.A., Mallinson P.I., Sheikh A., Abdul Kadir H., Tan T.J., Yan Y.Y. Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis. PLoS One. 2021; 16(12). doi:10.1371/journal.pone.0261657.; Cazzato R.L., Gantzer J., de Marini P., Garnon J., Koch G., Buy X., Autrusseau P.A., Auloge P., Dalili D., Kurtz J.E., Gangi A. Sporadic Desmoid Tumours: Systematic Review with Reflection on the Role of Cryoablation. Cardiovasc Intervent Radiol. 2022; 45(5): 613–21. doi:10.1007/s00270-022-03091-5.; Efrima B., Ovadia J., Drukman I., Khoury A., Rath E., Dadia S., Gortzak Y., Albagli A., Sternheim A., Segal O. Cryo-surgery for symptomatic extra-abdominal desmoids. A proof of concept study. J Surg Oncol. 2021; 124(4): 627–34. doi:10.1002/jso.26528.; Auloge P., Garnon J., Robinson J.M., Thenint M.A., Koch G., Caudrelier J., Weiss J., Cazzato R.L., Kurtz J.E., Gangi A. Percutaneous cryoablation for advanced and refractory extra-abdominal desmoidtumors. Int J Clin Oncol. 2021; 26(6): 1147–58. doi:10.1007/s10147021-01887-y.; Saltiel S., Bize P.E., Goetti P., Gallusser N., Cherix S., Denys A., Becce F., Tsoumakidou G. Cryoablation of Extra-Abdominal Desmoid Tumors: A Single-Center Experience with Literature Review. Diagnostics (Basel). 2020; 10(8): 556. doi:10.3390/diagnostics10080556.; Schmitz J.J., Schmit G.D., Atwell T.D., Callstrom M.R., Kurup A.N., Weisbrod A.J., Morris J.M. Percutaneous Cryoablation of Extraabdominal Desmoid Tumors: A 10-Year Experience. Am J Roentgenol. 2016; 207(1): 190–5. doi:10.2214/AJR.15.14391.; Redifer Tremblay K., Lea W.B., Neilson J.C., King D.M., Tutton S.M. Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. J Surg Oncol. 2019; 120(3): 366–75. doi:10.1002/jso.25597.; Bouhamama A., Lame F., Mastier C., Cuinet M., Thibaut A., Beji H., Ricoeur A., Blay J.Y., Pilleul F. Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors. Cardiovasc Intervent Radiol. 2020; 43(1): 110–9. doi:10.1007/s00270-019-02323-5.; Kurtz J.E., Buy X., Deschamps F., Sauleau E., Bouhamama A., Toulmonde M., Honoré C., Bertucci F., Brahmi M., Chevreau C., Duffaud F., Gantzer J., Garnon J., Blay J.Y., Gangi A. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021; 143: 78–87. doi:10.1016/j.ejca.2020.10.035.; Mandel J.E., Kim D., Yarmohammadi H., Ziv E., Keohan M.L., D’Angelo S.P., Gounder M.M., Whiting K., Qin L.X., Singer S., Crago A.M., Erinjeri J.P. Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Ann Surg Oncol. 2022; 29(1): 640–8. doi:10.1245/s10434021-10463-7.; Izadifar Z., Izadifar Z., Chapman D., Babyn P. An Introduction to High Intensity Focused Ultrasound: Systematic Review on Principles, Devices, and Clinical Applications. J Clin Med. 2020; 9(2): 460. doi:10.3390/jcm9020460.; Москвичева Л.И. Высокоинтенсивная фокусированная ультразвуковая абляция злокачественных новообразований молочной железы. Research and Practical Medicine Journal. 2018; 5(3): 67–76. doi:10.17709/2409-2231-2018-5-3-6.; Siedek F., Yeo S.Y., Heijman E., Grinstein O., Bratke G., Heneweer C., Puesken M., Persigehl T., Maintz D., Grüll H. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU): Technical Background and Overview of Current Clinical Applications (Part 1). Rofo. 2019; 191(6): 522–30. doi:10.1055/a-0817-5645.; Elhelf I.A.S., Albahar H., Shah U., Oto A., Cressman E., Almekkawy M. High intensity focused ultrasound: The fundamentals, clinical applications and research trends. Diagn Interv Imaging. 2018; 99(6): 349–59. doi:10.1016/j.dIII.2018.03.001.; Болотина Л.В., Москвичева Л.И., Корниецкая А.Л., Сидоров Д.В., Гришин Н.А., Ложкин М.В., Каприн А.Д. Предварительная оценка эффективности комбинированного лечения с включением HIFUтерапии у больных раком поджелудочной железы. Сибирский онкологический журнал. 2021; 20(3): 18–27. doi:10.21294/1814-4861-2021-20-3-18-27.; Москвичева Л.И. Применение HIFU-терапии в онкологии (2000–2021 гг.). Онкология. Журнал им. П.А. Герцена. 2022; 11(1): 64–74. doi:10.17116/onkolog20221101164.; Wang Y., Wang W., Tang J. Ultrasound-guided high intensity focused ultrasound treatment for extra-abdominal desmoid tumours: preliminary results. Int J Hyperthermia. 2011; 27(7): 648–53. doi:10.3109/02656736.2011.597047.; Zhao W.P., Han Z.Y., Zhang J., Yu X.L., Cheng Z.G., Zhou X., Liang P. Early experience: high-intensity focused ultrasound treatment for intra-abdominal aggressive fibromatosis of failure in surgery. Br J Radiol. 2016; 89(1062). doi:10.1259/bjr.20151026.; Zhang R., Chen J.Y., Zhang L., Li K.Q., Xiao Z.B., Mo S.J., Chen L., Chen W.Z. The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors. Int J Hyperthermia. 2021; 38(2): 89–95. doi:10.1080/02656736.2021.1894359.; Zhong X., Hu X., Zhao P., Wang Y., Fang X.F., Shen J., Shen H., Yuan Y. The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. Cancer Med. 2022; 11(10): 2079–84. doi:10.1002/cam4.4573.; Yang Y., Zhang J., Pan Y. Management of unresectable and recurrent intra-abdominal desmoid tumors treated with ultrasound-guided highintensity focused ultrasound: A retrospective single-center study. Medicine (Baltimore). 2022; 101(34). doi:10.1097/MD.0000000000030201.; Ghanouni P., Dobrotwir A., Bazzocchi A., Bucknor M., Bitton R., Rosenberg J., Telischak K., Busacca M., Ferrari S., Albisinni U., Walters S., Gold G., Ganjoo K., Napoli A., Pauly K.B., Avedian R. Magnetic resonanceguided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol. 2017; 27(2): 732–40. doi:10.1007/s00330-016-4376-5.; NajAFI A., Fuchs B., Binkert C.A. Mid-term results of MR-guided high-intensity focused ultrasound treatment for relapsing superficial desmoids. Int J Hyperthermia. 2019; 36(1): 538–42.; https://www.siboncoj.ru/jour/article/view/2764

Availability: https://www.siboncoj.ru/jour/article/view/2764
https://doi.org/10.21294/1814-4861-2023-22-5-96-104

Comparative analysis of minimally invasive methods of treatment of localized prostate cancer ; Сравнительный анализ малоинвазивных методов лечения локализованного рака предстательной железы

Authors: D. V. Chinenov, E. V. Shpot, Ya. N. Chernov, Z. K. Tsukkiev, A. Yu. Votyakov, A. A. Kurbanov, H. M. Ismailov, Yu. V. Lerner, L. M. Rapoport, Д. В. Чиненов, Е. В. Шпоть, Я. Н. Чернов, З. К. Цуккиев, А. Ю. Вотяков, А. А. Курбанов, Х. М. Исмаилов, Ю. В. Лернер, Л. М. Рапопорт

Source: Andrology and Genital Surgery; Том 23, № 2 (2022); 34-46 ; Андрология и генитальная хирургия; Том 23, № 2 (2022); 34-46 ; 2412-8902 ; 2070-9781

Subject Terms: локализованный рак предстательной железы, cryoablation, high-intensity focused ultrasound therapy, prostate cancer detection, криоабляция, высокоинтенсивная фокусированная ультразвуковая терапия

File Description: application/pdf

Relation: https://agx.abvpress.ru/jour/article/view/563/461; Pettersson A., Robinson D., Garmo H. et al. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 2018;29(2):377–85. DOI:10.1093/annonc/mdx742.; Wilt T.J., MacDonald R., Rutks I. et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148(6):435–48. DOI:10.7326/0003-4819-148-6200803180-00209.; Ficarra V., Novara G., Rosen R.C. et al. Systematic review and metaanalysis of studies reporting urinary continence recovery after robotassisted radical prostatectomy. Eur Urol 2012;62(3):405–17. DOI:10.1016/j.eururo.2012.05.045.; Morash C., Tey R., Agbassi C. et al. Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 2015;9(5–6):171–78. DOI:10.5489/cuaj.2806.; Richard P.O., Alibhai S.M., Panzarella T. et al. The uptake of active surveillance for the management of prostate cancer: a population-based analysis. Can Urol Assoc J 2016;10(9–10):333–8. DOI:10.5489/cuaj.3684.; Sankar A., Johnson S.R., Beattie W.S. et al. Reliability of the American Society of Anesthesiologists physical status scale in clinical practice. Br J Anaesth 2014;113(3):424–32. DOI:10.1093/bja/aeu100.; Cordeiro E.R., Cathelineau X., Thüroff S. et al. High-intensity focused ultra-sound (HIFU) for definitive treatment of prostate cancer. BJU Int 2012;110(9):1228–42. DOI:10.1111/j.1464-410X.2012.11262.x.; Wilt T.J., Brawer M.K., Jones K.M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203–3. DOI:10.1056/NEJMoa1113162.; Bill-Axelson A., Holmberg L., Garmo H. et. al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014:370(10):932–42. DOI:10.1056/NEJMoa1311593.; Chiang P.H., Liu Y.Y. Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer. Springerplus 2016;5(1):1905. DOI:10.1186/s40064-016-3584-4.; Tay K.J., Amin M.B., Ghai S. et al. Surveillance after prostate focal therapy. World J Urol 2019;37(3):397–407. DOI:10.1007/s00345-018-2363-y.; Muller B.G., van den Bos W., Brausi M. et al. Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int 2014;114(5):698–707. DOI:10.1111/bju.12548.; Zimmermann J.S., MD, Osieka R., Bruns T. et al. Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease. J Contemp Brachytherapy 2018;10(4):297–305. DOI:10.5114/jcb.2018.77949.; Fellin G., Mirri M.A., Santoro L. et al. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. Br J Radiol 2016;89(1065):20150981. DOI:10.1259/bjr.20150981.; Rodríguez S.A., Arias Fúnez F., Bueno Bravo C. et al. Cryotherapy for primary treatment of prostate cancer: intermediate term results of a prospective study from a single institution. Prostate Cancer 2014;2014:571576. DOI:10.1155/2014/571576.; Limani K., Aoun F., Holz S. et al. Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes. Prostate Cancer 2014;2014:186782. DOI:10.1155/2014/186782.; El Fegoun A.B., Barret E., Prapotnich D. et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 2011;37(2):213–9; discussion 220–2. DOI:10.1590/s1677-55382011000200008.; Ahmed H.U., Dickinson L., Charman S. et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 2015;68(6):927–36. DOI:10.1016/j.eururo.2015.01.030.; Feijoo E.R.C., Sivaraman A., Barret E. et al. Focal high intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur Urol 2016;69(2):214–20. DOI:10.1016/j.eururo.2015.06.018.; van der Poel H.G., van den Bergh R.C., Briers E. et al. Focal therapy in primary localised prostate cancer: The European Association of Urology position in 2018. Eur Urol 2018;74(1):84–91. DOI:10.1016/j.eururo.2018.01.001.; Mendez M.H., Passoni N.M., Pow-Sang J. et al. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol 2015;29(10):1193–8. DOI:10.1089/end.2014.0881.; Valerio M., Shah T.T., Shah P. et al. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: a prospective development study. Urol Oncol 2017;35(4):150.e1–e7. DOI:10.1016/j.urolonc.2016.11.008.; King M.T., Nguyen P.L., Boldbaatar N. et al. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer 2018;124(17):3528–35. DOI:10.1002/cncr.31568.; Merrick G.S., Butler W.M., Galbreath R.W. et al. Stratification of brachytherapytreated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts. J Contemp Brachytherapy 2015;7(6):430–6. DOI:10.5114/jcb.2015.56763.; Lucan V.C., Lugnani F., Butticè S. et al. Cryotherapy for low risk prostate cancer, oncological and functional medium term outcomes: a three center prospective study. Arch Ital Urol Androl 2017;89(2):97–101. DOI:10.4081/aiua.2017.2.97.; Schoentgen N., Marolleau J., Delage F. et al. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 >16. J Contemp Brachytherapy 2019;11(3):195–200. DOI:10.5114/jcb.2019.85793.; Liu Y.Y., Chiang P.H. Comparisons of oncological and functional outcomes between primary whole-gland cryoablation and high-intensity focused ultrasound for localized prostate cancer. Ann Surg Oncol 2016;23(1):328–34. DOI:10.1245/s10434-015-4686-x.; Wolff R.F., Ryder S., Bossi A. et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer 2015;51(16):2345–67. DOI:10.1016/j.ejca.2015.07.019.; Hatiboglu G., Popeneciu I.V., Deppert M. et al. Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer. BMC Urol 2017;17(1):5. DOI:10.1186/s12894-017-0198-2.; Onishi K., Tanaka N., Miyake M. et al. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. Clin Transl Radiat Oncol 2018;14:51–8. DOI:10.1016/j.ctro.2018.11.001.; Yu Y.D., Kang M.H., Choi C.I. et al. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer. World J Urol 2016;34(9):1269–74. DOI:10.1007/s00345-016-1777-7.; https://agx.abvpress.ru/jour/article/view/563

Availability: https://agx.abvpress.ru/jour/article/view/563
https://doi.org/10.17650/2070-9781-2022-23-2-34-46

Combined treatment of patients with localized pancreatic cancer of elderly and senile age ; Комбинированное лечение больных пожилого и старческого возраста с локализованным раком поджелудочной железы

Authors: L. I. Moskvicheva, L. V. Bolotina, A. L. Kornietskaya, D. V. Sidorov, N. A. Grishin, M. V. Lozhkin, A. D. Kaprin, Л. И. Москвичева, Л. В. Болотина, А. Л. Корниецкая, Д. В. Сидоров, Н. А. Гришин, М. В. Ложкин, А. Д. Каприн

Source: Meditsinskiy sovet = Medical Council; № 9 (2021); 122-128 ; Медицинский Совет; № 9 (2021); 122-128 ; 2658-5790 ; 2079-701X

Subject Terms: HIFU, adenocarcinoma, palliative care, chemotherapy, high-intensity focused ultrasound therapy, аденокарцинома, паллиативное лечение, химиотерапия, высокоинтенсивная фокусированная ультразвуковая терапия

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6257/5671; Москвичева Л.И., Болотина Л.В. Возможности химиотерапии у больных местно-распространенным и метастатическим аденогенным раком поджелудочной железы. Исследования и практика в медицине. 2020;7(4):118–134. https://doi.org/10.17709/2409-2231-2020-7-4-10.; Bradley A., Van Der Meer R. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Sci Rep. 2019;9(1):4354. https://doi.org/10.1038/s41598-019-40951-6.; Masiak-Segit W., Rawicz-Pruszyński K., Skórzewska M., Polkowski W.P. Surgical Treatment of Pancreatic Cancer. Pol Przegl Chir. 2018;90(2):45–53. https://doi.org/10.5604/01.3001.0011.7493.; Katz M.H., Marsh R., Herman J.M., Shi Q., Collison E., Venook A.P. et al. Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. Ann Surg Oncol. 2013;20(8):2787–2795. https://doi.org/10.1245/s10434-013-2886-9.; Katz M.H.G., Ou F.S., Herman J.M., Ahmad S.A., Wolpin B., Marsh R. et al. Alliance for Clinical Trials in Oncology (ALLIANCE) Trial A021501: Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas. BMC Cancer. 2017;17(1):505. https://doi.org/10.1186/s12885-017-3441-z.; Pędziwiatr M., Małczak P., Major P., Witowski J., Kuśnierz-Cabala B., Ceranowicz P., Budzyński A. Minimally Invasive Pancreatic Cancer Surgery: What Is the Current Evidence? Med Oncol. 2017;34(7):125. https://doi.org/10.1007/s12032-017-0984-4.; Zureikat A.H., Nguyen K.T., Bartlett D.L., Zeh H.J., Moser A.J. RoboticAssisted Major Pancreatic Resection and Reconstruction. Arch Surg. 2011;146(3):256–261. https://doi.org/10.1001/archsurg.2010.246.; Kendrick M.L., Cusati D. Total Laparoscopic Pancreaticoduodenectomy: Feasibility and Outcome in an Early Experience. Arch Surg. 2010;145(1):19–23. https://doi.org/10.1001/archsurg.2009.243.; Mohammed S., Van Buren G. 2nd, Fisher W.E. Pancreatic Cancer: Advances in Treatment. World J Gastroenterol. 2014;20(28):9354–9360. Available at: https://pubmed.ncbi.nlm.nih.gov/25071330.; Hüttner F.J., Fitzmaurice C., Schwarzer G., Seiler C.M., Antes G., Büchler M.W., Diener M.K. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2016;2:CD006053. https://doi.org/10.1002/14651858.CD006053.pub6.; Strobel O., Hank T., Hinz U., Bergmann F., Schneider L., Springfeld C. et al. Pancreatic Cancer Surgery: The New R-status Counts. Ann Surg. 2017;265(3):565–573. https://doi.org/10.1097/SLA.0000000000001731.; Hank T., Hinz U., Tarantino I., Kaiser J., Niesen W., Bergmann F. et al. Validation of at Least 1 mm as Cut-Off for Resection Margins for Pancreatic Adenocarcinoma of the Body and Tail. Br J Surg. 2018;105(9):1171–1181. https://doi.org/10.1002/bjs.10842.; Niesen W., Hank T., Büchler M., Strobel O. Local Radicality and Survival Outcome of Pancreatic Cancer Surgery. Ann Gastroenterol Surg. 2019;3(5):464–475. https://doi.org/10.1002/ags3.12273.; Witzigmann H., Diener M.K., Kienkötter S., Rossion I., Bruckner T., Bärbel W. et al. No Need for Routine Drainage After Pancreatic Head Resection: The Dual-Center, Randomized, Controlled PANDRA Trial (ISRCTN04937707). Ann Surg. 2016;264(3):528–537. https://doi.org/10.1097/SLA.0000000000001859.; Ejaz A., He J. Pancreaticoduodenectomy for Pancreatic Cancer: Perspective from the United States. Chin Clin Oncol. 2017;6(1):1. https://doi.org/10.21037/cco.2017.02.01.; Adam M.A., Choudhury K., Dinan M.A., Reed S.D., Scheri R.P., Blazer D.G. 3rd et al. Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes among 7061 Patients. Ann Surg. 2015;262(2):372–377. https://doi.org/10.1097/SLA.0000000000001055.; Petrelli F., Coinu A., Borgonovo K., Cabiddu M., Ghilardi M., Lonati V. et al. FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Metaanalytical Review of Published Studies. Pancreas. 2015;44(4):515–521. https://doi.org/10.1097/mpa.0000000000000314.; Gillen S., Schuster T., Meyer Zum Buschenfelde C., Friess H., Kleeff J. Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Response and Resection Percentages. PLoS Med. 2010;7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267.; O’Reilly E.M., Perelshteyn A., Jarnagin W.R., Schattner M., Gerdes H., Capanu M. et al. A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients with Resectable Pancreas Adenocarcinoma. Ann Surg. 2014;260(1):142–148. https://doi.org/10.1097/SLA.0000000000000251.; Heinrich S., Pestalozzi B., Schafer M., Weber A., Bauerfeind P., Knuth A., Clavien P. Prospective Phase II Trial on Neoadjuvant Chemotherapy with Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. J Clin Oncol. 2008;26(15):2526–2531. https://doi.org/10.1200/JCO.2007.15.5556.; D’Angelo F., Antolino L., Farcomeni A., Sirimarco D., Kazemi Nava A., De Siena M. et al. Neoadjuvant Treatment in Pancreatic Cancer: EvidenceBased Medicine? A Systematic Review and Meta-Analysis. Med Oncol. 2017;34(5):85. https://doi.org/10.1007/s12032-017-0951-0.; Versteijne E., Vogel J.A., Besselink M.G., Busch O.R.C., Wilmink J.W., Daams J.G. et al. Meta-Analysis Comparing Upfront Surgery with Neoadjuvant Treatment in Patients with Resectable or Borderline Resectable Pancreatic Cancer. Br J Surg. 2018;105(8):946–958. https://doi.org/10.1002/bjs.10870.; Park H.M., Park S.J., Han S.S., Kim S.H. Surgery for Elderly Patients with Resectable Pancreatic Cancer, a Comparison with Non-Surgical Treatments: A Retrospective Study Outcomes of Resectable Pancreatic Cancer. BMC Cancer. 2019;19(1):1090. https://doi.org/10.1186/s12885-019-6255-3.; Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местнораспространенном раке поджелудочной железы. Исследования и практика в медицине. 2018;5(2):86–99. https://doi.org/10.17709/2409-2231-2018-5-2-10.; Сулейманов Э.А., Филоненко Е.В., Москвичева Л.И., Каприн А.Д., Костин А.А., Самсонов Ю.В., Исаев А.Р. Возможности HIFU-терапии на современном этапе. Исследования и практика в медицине. 2016;3(3):76–82. https://doi.org/10.17709/2409-2231-2016-3-3-8.; Хитрова А.Н., Болотина Л.В., Корниецкая А.Л., Москвичева Л.И. Проведение высокоинтенсивной фокусированной ультразвуковой терапии в рамках комбинированного лечения неоперабельной больной раком поджелудочной железы. Онкология. Журнал им. П.А. Герцена. 2020;9(1):50–54. https://doi.org/10.17116/onkolog2020901150.; Tao S.F., Gu W.H., Gu J.C., Zhu M.L., Wang Q., Zheng L.Z. A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer. Onco Targets Ther. 2019;12:9735–9745. https://doi.org/10.2147/OTT.S220299.

Availability: https://www.med-sovet.pro/jour/article/view/6257
https://doi.org/10.21518/2079-701X-2021-9-122-128

Modern methods of ablation of malignant tumors of the liver ; Современные методы абляции злокачественных новообразований печени

Authors: L. I. Moskvicheva, D. V. Sidorov, M. V. Lozhkin, L. O. Petrov, M. V. Zabelin, Л. И. Москвичева, Д. В. Сидоров, М. В. Ложкин, Л. О. Петров, М. В. Забелин

Source: Research and Practical Medicine Journal; Том 5, № 4 (2018); 58-71 ; Research'n Practical Medicine Journal; Том 5, № 4 (2018); 58-71 ; 2410-1893 ; 10.17709/2409-2231-2018-5-4

Subject Terms: стереотаксическая лучевая терапия, hepatocellular carcinoma, hepatic metastases, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound therapy, laser ablation, cryoablation, percutaneous ethanol injection, irreversible electroporation, stereotactic body radiation therapy, метастатическое поражение печени, радиочастотная абляция, микроволновая абляция, высокоинтенсивная фокусированная ультразвуковая терапия, лазерная абляция, криоабляция, химическая абляция, необратимая электропорация

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/322/272; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. Каприна А. Д., Ста-ринского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России; 2017, 250 с./Ma-lignant neoplasms in Russia in 2015 (morbidity and mortality). Edited by Kaprin A. D., Starinsky V. V., Petrova G. V. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2017, р. 250 (In Russian).; Состояние онкологической помощи населению России в 2017 году. Под ред. Каприна А. Д., Старинского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018, 236 с./The state of cancer care in Russia in 2017. Edited by Kaprin A. D., Starinsky V. V., Petrova G. V. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2018, р. 236 (In Russian).; Лунев С. В., Сельчук В. Ю., Чистяков С. С. Современные подходы к хирургическому лечению опухолей печени. Русский медицинский журнал. 2011;2:44-47./Lunev SV, Selchuk VYu, Chistyakov SS. Modern approaches to surgical treatment of liver tumors. Russian Medical Journal. 2011;2:44-47. (In Russian).; Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schal-ke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014 Nov 4;14:810. DOI:10.1186/1471-2407-14-810; de Haas RJ, Wicherts DA, Flores E, Ducreux M, Levi F, Paule B, et al. Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases. Ann Surg Oncol. 2010 Apr;17 (4):1010-23. DOI:10.1245/s10434-009-0887-5.; Вишневский В. А., Ефанов М. Г., Икрамов Р. З., Чжао А. В. Опухоли печени: диагностика и хирургическое лечение. Доказательная гастроэнтерология. 2013;2:38-47./Vishnevsky VA, Efanov MG, Ikramov RZ, Zhao AV. Hepatic tumours: diagnostics and surgical treatment. Russian Journal of Evidence-Based Gastroenterology (Dokazatel'naya gastroenterologiya). 2013;2:38-47. (In Russian).; Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. Gastroenterology. 2004 Nov;127 (5 Suppl 1): S35-50.; Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359 (4):378-90. DOI:10.1056/NEJMoa0708857; Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregion-al therapies in cholangiocarcinoma. Hepat Oncol. 2017 Oct;4 (4):99-109. DOI:10.2217/hep-2017-0014; Hansen PD, Cassera MA, Wolf RF. Ablative technologies for hepatocellular, cholangiocarcinoma, and metastatic colorectal cancer of the liver. Surg Oncol Clin N Am. 2015 Jan;24 (1):97-119. DOI:10.1016/j.soc.2014.09.003.; Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol. 2013 Dec;16 (4):192-200. DOI:10.1053/j.tvir.2013.08.002.; Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008 Feb;32 (2):481-90.; Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009 Mar;13 (3):486-91. DOI:10.1007/s11605-008-0727-0.; Agcaoglu O, Aliyev S, Karabulut K, El-Gazzaz G, Aucejo F, Pel-ley R, et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg. 2013 Jun;37 (6):1333-9. DOI:10.1007/s00268-013-1981-1; Razafindratsira Т, Isamber М, Evrard S. Complications of intraoperative radiofrequency ablation of liver metastases. HPB. 2011;13:15-23. https://doi.org/10.1111/j.1477-2574.2010.00243.x; Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008 Oct;15 (10):2757-64. DOI:10.1245/s10434-008-0043-7; Nielsen K, van Tilborg AA, Meijerink MR, Macintosh MO, Zon-derhuis BM, de Lange ES, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013 Jun;37 (6):1340-7. DOI:10.1007/s00268-013-1997-6.; Van Tilborg AA, Meijerink MR, Sietses C, Van Waesberghe JH, Mackintosh MO, Meijer S, et al. Long term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011 Jun;84 (1002):556-65. DOI:10.1259/bjr/78268814.; Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011 Jul;81 (1):25-34. DOI:10.4174/jkss.2011.81.1.25; Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012 Oct;23 (10):2619-26. DOI:10.1093/annonc/mds053; Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017 Sep 1;109 (9). DOI:10.1093/jnci/djx015.; Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013 Jan;58 (1):89-97. DOI:10.1016/j.jhep.2012.09.020; Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 2005 Sep;11 (9):1117-26. DOI:10.1002/lt.20469; Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006 May;186 (5 Suppl): S296-305. DOI:10.2214/AJR.04.1927; Sun Y, Cheng Z, Dong L, Zhang G, Wang Y, Liang P. Comparison of temperature curve and ablation zone between 915-and 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine livers. Eur J Radiol. 2012 Mar;81 (3):553-7. DOI:10.1016/j.ejrad.2011.02.013.; Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, et al. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. J Vasc Interv Radiol. 2018 Feb;29 (2):268-275.e1. DOI:10.1016/j.jvir.2017.08.021.; Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017 Feb 9;8 (31):51792-51799. DOI:10.18632/oncotarget.15244.; Zhou F, Yu X, Liang P, Han Z, Cheng Z, Yu J, et al. Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? — Lessons from 10 years' experience. Oncotarget. 2017 Jun 28;8 (59):100791-100800. DOI:10.18632/oncotarget.18764.; Livraghi T, Meloni F, Solbiati L, Zanus G, Noto A, Goleffi O, et al. Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol. 2012 Aug;35 (4):868—74. DOI:10.1007/s00270-011-0241-8; Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000 Jul 15;89 (2):276-84.; Alexander ES, Wolf FJ, Machan JT, Charpentier KP, Beland MD, Iannuccilli JD, et al. Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patients. Eur J Radiol. 2015 Jun;84 (6):1083-90. DOI:10.1016/j. ejrad.2015.02.027; Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol. 2015 Aug;26 (8):1139-1146.e2. DOI:10.1016/j.jvir.2015.04.004.; Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015 Mar 15;111 (4):410-3. DOI:10.1002/jso.23849.; Sun AX, Cheng ZL, Wu PP, Sheng YH, Qu XJ, Lu W, et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World J Gastroenterol. 2015 Mar 14;21 (10):2997-3004. DOI:10.3748/wjg.v21.i10.2997.; Ginsburg M, Zivin SP, Wroblewski K, Doshi T, Vasnani RJ, Van Ha TG. Comparison of Combination Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboli-zation with Radiofrequency Ablation versus Microwave Ablation. J Vasc Interv Radiol. 2015 Mar;26 (3):330-41. DOI:10.1016/j.jvir.2014.10.047.; van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Futter-er JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017 Feb;66 (2):247-258. DOI:10.1007/s00262-016-1891-9.; Dupre A, Melodelima D, Perol D, Chen Y, Vincenot J, Chapelon JY, Rivoire M. First Clinical Experience of Intra-Operative High Intensity Focused Ultrasound in Patients with Colorectal Liver Metastases: A Phase I-IIa Study. PLoS One. 2015 Feb 26;10 (2): e0118212. DOI:10.1371/journal.pone.0118212.; Mearini L. High intensity focused ultrasound, liver disease and bridging therapy. World J Gastroenterol. 2013 Nov 21;19 (43):7494-9. DOI:10.3748/wjg.v19.i43.7494.; Li JJ, Gu MF, Luo GY, Liu LZ, Zhang R, Xu GL. Complications of high intensity focused ultrasound for patients with hepatocellular carcinoma. Technol Cancer Res Treat. 2009 Jun;8 (3):217-24. DOI:10.1177/153303460900800306; Xu G, Luo G, He L, Li J, Shan H, Zhang R, Li Y, et al. Follow-up of high-intensity focused ultrasound treatment for patients with hepatocellular carcinoma. Ultrasound Med Biol. 2011 Dec;37 (12):1993-9. DOI:10.1016/j.ultrasmedbio.2011.08.011; Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, Chu F, et al. High-intensity focused ultrasound for hepatocellular carcinoma. Ann Surg. 2011 May;253 (5):981-7. DOI:10.1097/SLA.0b013e3182128a8b.; Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, et al. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford). 2013 Aug;15 (8):567-73. DOI:10.1111/hpb.12025.; Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, et al. Advanced hepatocellular carcinoma: treatment with high intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005 May;235 (2):659-67. DOI:10.1148/ra-diol.2352030916; Vogl TJ, Farshid P, Naguib NN, Darvishi A, Bazrafshan B, Mbal-isike E, et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014 Jul;119 (7):451-61. DOI:10.1007/s11547-014-0415-y; Di Costanzo GG, D'Adamo G, Tortora R, Zanfardino F, Mat-tera S, Francica G, Pacella CM. A novel needle guide system to perform percutaneous laser ablation of liver tumors using the multifiber technique. Acta Radiol. 2013 Oct;54 (8):876-81. DOI:10.1177/0284185113489825.; Tombesi P, Di Vece F, Sartori S. Laser ablation for hepatic metastases from neuroendocrine tumors. AJR Am J Roentgenol. 2015 Jun;204 (6): W732. DOI:10.2214/AJR.14.14242.; Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7 (4):477-489. DOI:10.4292/wjgpt.v7.i4.477; Yu H, Burke CT. Comparison of Percutaneous Ablation Technologies in the Treatment of Malignant Liver Tumors. Semin Intervent Radiol. 2014 Jun;31 (2):129-37. DOI:10.1055/s-0034-1373788.; Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol. 2012 Oct;46 (9):796-801. DOI:10.1097/MCG.0b013e3182641806; Sartori S, Di Vece F, Ermili F, Tombesi P. Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave? World J Radiol. 2017 Mar 28;9 (3):91-96. doi:10.4329/wjr.v9.i3.91.; Di Costanzo GG, Tortora R, D'Adamo G, De Luca M, Lampasi F, Addario L, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol. 2015 Mar;30 (3):559-65. DOI:10.1111/jgh.12791.; Qu J, Gao X, Chen Y, Zhou L, Wu Y, Feng Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012 Nov;19 (6):674-84. DOI:10.1007/s00534-011-0490-6.; Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to LongTerm Outcomes. AJR Am J Roentgenol. 2017 Dec;209 (6):1381-1389. DOI:10.2214/AJR.16.17582; Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010 Jul;22 (4):364-73. DOI:10.1097/CCO.0b013e32833a6c8a; Wu B, Xiao YY, Zhang X, Zhang AL, Li HJ, Gao DF. Magnetic resonance imaging-guided percutaneous cryoablation of hepatocellular carcinoma in special regions. Hepatobiliary Pancreat Dis Int. 2010 Aug;9 (4):384-92.; Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, et al. Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. PLoS One. 2015 Apr 7;10 (4): e0123065. DOI:10.1371/journal.pone.0123065; Xu K-C, Niu L-Z, He W-B, Hu Y-Z, Zuo J-S. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol. 2008 Mar 7;14 (9):1430-6.; Shimizu T, Sakuhara Y, Abo D, Hasegawa Y, Kodama Y, Endo H, et al. Outcome of MR-guided percutaneous cryoabla-tion for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009;16:816-823. https://doi.org/10.1007/s00534-009-0124-4; Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porche-ron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007 Jun;33 (5):590-6. DOI:10.1016/j.ejso.2007.01.003; Xu K-C, Niu L-Z, Zhou Q, Hu Y-Z, Guo D-H, Liu Z-P, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009 Aug 7;15 (29):3664-9.; McCarley JR, Soulen MC. Percutaneous ablation of hepatic tumors. Semin Intervent Radiol. 2010 Sep;27 (3):255-60. DOI:10.1055/s-0030-1261783.; Mahnken AH, Bruners P, Gunther RW. Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Dig Dis. 2009;27 (2):148-56. DOI:10.1159/000218347.; Kwon JH. Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation? Gut Liver. 2010 Sep;4 Suppl 1: S105-12. DOI:10.5009/gnl.2010.4.S1.S105; Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005 May;31 (4):331-47. DOI:10.1016/j.ejso.2004.10.011; Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farel-la N, Mariniello A, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011 Jun;31 (6):2291-5.; Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol. 2012 Mar 14;18 (10):1003-8. DOI:10.3748/wjg. v18.i10.1003; Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshika-wa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year ob-servation. J Hepatol. 2005 Sep;43 (3):458-64. DOI:10.1016/j.jhep.2005.03.033; Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol. 2006 Jun 21;12 (23):3707-15.; Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2005 Jul;92 (7):856-8. DOI:10.1002/bjs.4986; Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003 Feb;237 (2):171-9. DOI:10.1097/01.SLA.0000048443.71734.BF; Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005 Aug;54 (8):1151-6. DOI:10.1136/gut.2004.045203; Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007 Aug;244 (2):599-607. DOI:10.1148/radi-ol.2442060826; Branco F, Bru C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol. 2009 Jul-Sep;8 (3):220-7.; Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017 Mar 13;4:49-58. DOI:10.2147/JHC.S129063.; Qasrawi R, Silve L, Burdio F, Abdeen Z, Ivorra A. Anatomically Realistic Simulations of Liver Ablation by Irreversible Electroporation: Impact of Blood Vessels on Ablation Volumes and Undertreatment. Technol Cancer Res Treat. 2017 Jan 1:1533034616687477. DOI:10.1177/1533034616687477.; Ruarus AH, Vroomen LGPH, Puijk RS, Scheffer HJ, Zonderhu-is BM, Kazemier G, et al. Irreversible Electroporation in Hepa-topancreaticobiliary Tumours. Can Assoc Radiol J. 2018 Feb;69 (1):38-50. DOI:10.1016/j.carj.2017.10.005.; Dollinger M, Muller-Wille R, Zeman F, Haimerl M, Niessen C, Beyer LP, et al. Irreversible electroporation of malignant hepatic tumors — alterations in venous structures at subacute follow-up and evolution at mid-term follow-up. PLoS One. 2015 Aug 13;10 (8): e0135773. DOI:10.1371/journal.pone.0135773.; Dollinger M, Zeman F, Niessen C, Lang SA, Beyer LP, Muller M, et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J Vasc Interv Radiol. 2016 Jan;27 (1):96-103. DOI:10.1016/j.jvir.2015.10.002; Niessen C, Beyer LP, Pregler B, Dollinger M, Trabold B, Schlit-t=HJ, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: a prospective safety and midterm efficacy study in 34 patients. J Vasc Interv Radiol. 2016 Apr;27 (4):480-6. DOI:10.1016/j.jvir.2015.12.025; Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RCG. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016 Jul;18 (7):593-9. DOI:10.1016/j.hpb.2016.03.609; Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016 Nov;6 (1):34-43. DOI:10.1159/000449346; Lyu T, Wang X, Su Z, Shangguan J, Sun C, Figini M, et al. Irreversible electroporation in primary and metastatic hepatic malignancies. A review. Medicine (Baltimore). 2017 Apr;96 (17): e6386. DOI:10.1097/MD.0000000000006386.; Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous Irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017 Mar 7;7:43687. DOI:10.1038/srep43687; Scorseffi M, Comito T, Tozzi A, Navarria P, Fogliata A, Cleri-ci E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015 Mar;141 (3):543—53. doi:10.1007/s00432-014-1833-x; Mutsaers A, Greenspoon J, Walker-Dilks C, Swaminath A. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiat Oncol. 2017 Jun 29;12 (1):110. DOI:10.1186/s13014-017-0818-8.; Liu X, Song Y, Liang P, Su T, Zhang H, Zhao X, et al. Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients. Onco Targets Ther. 2017 Nov 6;10:5289-5295. DOI:10.2147/OTT.S142025.; Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol. 2017 Oct 19;12 (1):163. DOI:10.1186/s13014-017-0899-4; Деньгина Н. В., Мозерова Е. Я. Стереотаксическая лучевая терапия и локальная гипертермия в лечении опухолей различных локализаций. Практическая онкология. 2015;16 (4):162-173./Dengina NV, Mozerova EYa. Stereotactic body radiotherapy and local hyperthermia in the treatment of various malignant tumors. Practical Oncology. 2015;16 (4):162-173 (In Russian).; Kim TH, Park J-W, Kim BH, Kim DY, Moon SH, Kim SS, et al. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017 Dec 19;9 (3):4034-4043. DOI:10.18632/oncotarget.23428.; Mendez Romero A, Keskin-Cambay F, van Os RM, Nuyt-tens JJ, Heijmen BJM, IJzermans JNM, Verhoef C. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017 Mar-Apr;22 (2):126-131. DOI:10.1016/j.rpor.2016.10.003; Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundar-araman S, D'Ambrosio D, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis — clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018 Feb 13;13 (1):26. DOI:10.1186/s13014-018-0969-2.; https://www.rpmj.ru/rpmj/article/view/322

Availability: https://www.rpmj.ru/rpmj/article/view/322
https://doi.org/10.17709/2409-2231-2018-5-4-6

High-intensity focused ultrasonic ablation of breast cancer ; Высокоинтенсивная фокусированная ультразвуковая абляция злокачественных новообразований молочной железы

Authors: L. I. Moskvicheva, Л. И. Москвичева

Source: Research and Practical Medicine Journal; Том 5, № 3 (2018); 67-76 ; Research'n Practical Medicine Journal; Том 5, № 3 (2018); 67-76 ; 2410-1893 ; 10.17709/2409-2231-2018-5-3

Subject Terms: термическая абляция, breast fibroadenoma, high-intensity focused ultrasound, HIFU, thermal ablation, фиброаденомы молочной железы, высокоинтенсивная фокусированная ультразвуковая терапия, HIFU-терапия

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/294/255; Состояние онкологической помощи населению России в 2015 году. Под редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ “НМИЦР” Минздрава России. 2016. 236 с. Доступно по: http://www.oncology.ru/service/statistics/condition/2015.pdf; Бит-СаваЕ.М.,ЕгоренковВ.В.,ДамениаА.О.,МельниковаО.А., Ахмедов Р.М., Моногарова М.А., и др. Новые подходы в хирургии рака молочной железы. Практическая онкология. 2017;18(3):232-245.; Mauri G, Sconfienza LM, Pescatori LC, Fedeli MP, Alì M, Di Leo G, Sardanelli F. Technical success, technique efficacy and complications of minimally invasive imaging-guided percutaneous ablation procedures of breast cancer: a systematic review and meta-analysis. Eur Radiol. 2017 Aug;27(8):3199-3210. DOI:10.1007/s00330-016-4668-9.; Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. Eur J Surg Oncol. 2010 Dec;36(12):1149-55. DOI:10.1016/j.ejso.2010.09.012; Maloney E, Hwang JH. Emerging HIFU applications in cancer therapy. Int J Hyperthermia. 2015 May;31(3):302-9. DOI:10.3109/02656736.2014.969789.; Peek MCL, Wu F. High-intensity focused ultrasound in the treatment of breast tumours. Ecancermedicalscience. 2018 Jan 10;12:794. DOI:10.3332/ecancer.2018.794. eCollection 2018.; Hynynen K, Pomeroy O, Smith DN, Huber PE, McDannold NJ, Kettenbach J, et al. MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. Radiology. 2001;219(1):176–185. DOI:10.1148/radiology.219.1.r01ap02176; Cavallo Marincola B, Pediconi F, Anzidei M, Miglio E, Di Mare L, Telesca M, et al. High-intensity focused ultrasound in breast pathology: non-invasive treatment of benign and malignant lesions. Expert Rev Med Devices. 2015 Mar;12(2):191-9. DOI:10.1586/17434440.2015.986096; Kovatcheva R, Guglielmina JN, Abehsera M, Boulanger L, Laurent N, Poncelet E. Ultrasound-guided high-intensity focused ultrasound treatment of breast fibroadenoma – a multicenter experience. J Ther Ultrasound. 2015 Jan 22;3(1):1. DOI:10.1186/s40349-014-0022-3.; Peek MC, Ahmed M, Scudder J, Baker R, Pinder SE, Douek M. High intensity focused ultrasound in the treatment of breast fibroadenomata: results of the HIFU-F trial. Int J Hyperthermia. 2016;32(8):881-8. DOI:10.1080/02656736.2016.1212278; Kovatcheva R, Zaletel K, Vlahov J, Stoinov J. Long-term efficacy of ultrasound-guided high-intensity focused ultrasound treatment of breast fibroadenoma. J Ther Ultrasound. 2017 Mar 16;5:1. DOI:10.1186/s40349-017-0083-1.; Guan L, Xu G. Damage effect of high-intensity focused ultrasound on breast cancer tissues and their vascularities. World J Surg Oncol. 2016 May 26;14(1):153. doi:10.1186/s12957-0160908-3.; Wu F, Wang Z-B, Cao Y-De, Chen W-Z, Bai J, Zou J-Z, Zhu H. A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br J Cancer. 2003 Dec 15;89(12):2227-33.; van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Fütterer JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017 Feb;66(2):247-258. DOI:10.1007/s00262016-1891-9; Merckel LG, Knuttel FM, Deckers R, van Dalen T, Schubert G, Peters NH, et al. First clinical experience with a dedicated MRIguided high-intensity focused ultrasound system for breast cancer ablation. Eur Radiol. 2016 Nov;26(11):4037-4046. DOI:10.1007/s00330-016-4222-9; Li S, Wu PH. Magnetic resonance image-guided versus ultrasound-guided high-intensity focused ultrasound in the treatment of breast cancer. Chin J Cancer. 2013 Aug;32(8):441-52. DOI:10.5732/cjc.012.10104; Schmitz AC, Gianfelice D, Daniel BL, Mali WP, van den Bosch MA. Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions. Eur Radiol. 2008 Jul;18(7):1431-41. DOI:10.1007/s00330-008-0906-0; Gianfelice D, Khiat A, Amara M, Belblidia A, Boulanger Y. MR imaging-guided focused ultrasound surgery of breast cancer: correlation of dynamic contrast-enhanced MRI with histopathological findings. Breast Cancer Res Treat. 2003 Nov;82(2):93-101. DOI:10.1023/B:BREA.0000003956.11376.5b; Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, et al. Extracorporeal high intensity focused ultrasound treatment for patients with breast cancer. Breast Cancer Res Treat. 2005 Jul;92(1):5160. DOI:10.1007/s10549-004-5778-7; Furusawa H, Namba K, Nakahara H, Tanaka C, Yasuda Y, Hirabara E, et al. The evolving non-surgical ablation of breast cancer: MR guided focused ultrasound (MRgFUS). Breast Cancer. 2007;14(1):55-8. DOI:10.2325/jbcs.14.55; Kim SH, Jung SE, Kim HL, Hahn ST, Park GS, Park WC. The potential role of dynamic MRI in assessing the effectiveness of high-intensity focused ultrasound ablation of breast cancer. Int J Hyperthermia. 2010;26(6):594-603. DOI:10.3109/02656736.2010.481275; Gianfelice D, Khiat A, Boulanger Y, Amara M, Belblidia A. Feasibility of magnetic resonance imaging-guided focused ultrasound surgery as an adjunct to tamoxifen therapy in highrisk surgical patients with breast carcinoma. J Vasc Interv Radiol. 2003 Oct;14(10):1275-82.; Peek MC, Ahmed M, Napoli A, ten Haken B, Mc Williams S, Usiskin SI, et al. Systematic review of high intensity focused ultrasound ablation in the treatment of breast cancer. Br J Surg. 2015 Jul;102(8):873-82; discussion 882. DOI:10.1002/bjs.9793.; Hsiao YH, Kuo SJ, Tsai HD, Chou MC, Yeh GP. Clinical Application of High-intensity Focused Ultrasound in Cancer Therapy. J Cancer. 2016 Jan 3;7(3):225-31. DOI:10.7150/jca.13906; Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Vigna PD, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol. 2010 Sep;195(3):W245-52. DOI:10.2214/AJR.09.3321; Yu T, Luo J. Adverse events of extracorporeal ultrasound-guided high intensity focused ultrasound therapy. PLoS One. 2011;6(12):e26110. DOI:10.1371/journal.pone.0026110.; Peek MCL, Douek M. Ablative techniques for the treatment of benign and malignant breast tumours. J Ther Ultrasound. 2017 Jul 3;5:18. DOI:10.1186/s40349-017-0097-8; https://www.rpmj.ru/rpmj/article/view/294

Availability: https://www.rpmj.ru/rpmj/article/view/294
https://doi.org/10.17709/2409-2231-2018-5-3-6

THE POSSIBILITIES OF MODERN METHODS OF ABLATION IN NON-RESECTABLE LOCALLY ADVANCED PANCREATIC CANCER ; ВОЗМОЖНОСТИ СОВРЕМЕННЫХ МЕТОДОВ АБЛЯЦИИ ПРИ НЕРЕЗЕКТАБЕЛЬНОМ МЕСТНО-РАСПРОСТРАНЕННОМ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ

Authors: L. I. Moskvicheva, L. O. Petrov, D. V. Sidorov, Л. И. Москвичева, Л. О. Петров, Д. В. Сидоров

Source: Research and Practical Medicine Journal; Том 5, № 2 (2018); 86-99 ; Research'n Practical Medicine Journal; Том 5, № 2 (2018); 86-99 ; 2410-1893 ; 10.17709/2409-2231-2018-5-2

Subject Terms: фотодинамическая терапия, radiofrequency ablation, microwave ablation, high intensity focused ultrasound therapy, cryoablation, irreversible electroporation, stereotactic body radiotherapy, photodynamic therapy, радиочастотная абляция, микроволновая абляция, высокоинтенсивная фокусированная ультразвуковая терапия, криоабляция, необратимая электропорация, стереотаксическая лучевая терапия

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/272/244; Состояние онкологической помощи населению России в 2016 году. Под редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ “ФМИРЦ” Минздрава России. 2017.; Камарли З.П., Туманбаев А.М., Доолотбеков С.М. Рак поджелудочной железы: эпидемиология, клиника, диагностика, лечение. Вестник КРСУ. 2013;13(1):117-122.; Котельников А.Г., Патютко Ю.И., Трякин А.А. Клинические рекомендации по диагностике и лечению злокачественных опухолей поджелудочной железы. Общероссийский союз общественных объединений Ассоциация онкологов России, 2014. с. 28.; Макаров Е.С., Нечушкин М.И. Современные возможности лучевоголеченияракаоргановбилиопанкреатодуоденальной зоны. Практическая онкология. 2004;5(2):135-144.; Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013 Jan;398(1):63-9. DOI:10.1007/s00423-012-1011-z; Liu Q, Zhai B, Yang W, Yu LX, Dong W, He YQ, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther. 2009 Dec;17(12):2049-57. DOI:10.1038/mt.2009.221.; Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010 May;138(5):1931-42. DOI:10.1053/j.gastro.2009.12.051; Shah DR, Green S, Elliot A, McGahan JP, Khatri VP. Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol. 2013;5:71-80. https://doi.org/10.4251/wjgo.v5.i4.71; Paiella S, Salvia R, Girelli R, Frigerio I, Giardino A, D’Onofrio M, et al. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer. Updates Surg. 2016 Sep;68(3):307-311. DOI:10.1007/s13304-016-0385-9; Kallis Y, Phillips N, Steel A, Kaltsidis H, Vlavianos P, Habib N, Westaby D. Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit. Dig Dis Sci. 2015 Nov;60(11):3449-55. doi:10.1007/s10620-015-3731-8.; Wu TT, Li HC, Li WM, Ao GK, Lin H, Zheng F, Song JY. Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extra hepatic Biliary Obstruction: A Safe and Feasible Method. Dig Dis Sci. 2015;60(7):2158-63. Dig Dis Sci. 2015 Jul;60(7):2158-63. DOI:10.1007/s10620-015-3547-6; Wang J, Zhao L, Zhou C, Gao K, Huang Q, Wei B, Gao J. Percutaneous Intraductal Radiofrequency Ablation Combined with Biliary Stent Placement for Nonresectable Malignant Biliary Obstruction Improves Stent Patency but not Survival. Medicine (Baltimore). 2016 Apr;95(15):e3329. DOI:10.1097/MD.0000000000003329.; Rustagi T, Chhoda A. Endoscopic Radiofrequency Ablation of the Pancreas. Dig Dis Sci. 2017 Apr;62(4):843-850. DOI:10.1007/s10620-017-4452-y; Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh DW, Park DH, et al. Initial experience of EUS guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016 Feb;83(2):440-3. DOI:10.1016/j.gie.2015.08.048; Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cicinnati VR, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms andneuroendocrine tumors. World J Gastrointest Surg. 2015 Apr 27;7(4):52-9. DOI:10.4240/ wjgs.v7.i4.52.; Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. J Vasc Interv Radiol. 2014 Nov;25(11):1691-705.e4. DOI:10.1016/j.jvir.2014.08.027; Lygidakis NJ, Sharma SK, Papastratis P, Zivanovic V, Kefalourous H, Koshariya M, et al. Microwave ablation in locally advanced pancreatic carcinoma – a new look. Hepatogastroenterology. 2007;54:1305–1310.; Carrafiello G, Ierardi AM, Fontana F, Petrillo M, Floridi C, Lucchina N, et al. Microwave ablation of pancreatic head cancer: safety and efficacy. J Vasc Interv Radiol. 2013 Oct;24(10):1513-20. DOI:10.1016/j.jvir.2013.07.005.; Van den Bijgaart RJE, Eikelenboom DC, Hoogenboom M, Fütterer JJ, den Brok MH, Gosse J. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. J Vasc Interv Radiol. 2013 Oct;24(10):1513-20. DOI:10.1016/j.jvir.2013.07.005; Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract. 2014;2014:205325. DOI:10.1155/2014/205325.; Wu F. High intensity focused ultrasound: a noninvasive therapy for locally advanced pancreatic cancer. World J Gastroenterol. 2014 Nov 28;20(44):16480-8. DOI:10.3748/wjg.v20.i44.16480.; Diana M, Schiraldi L, Liu Y-Y, Memeo R, Mutter D, Pessaux P, Marescaux J. High intensity focused ultrasound (HIFU) applied to hepato-biliopancreatic and the digestive system – current state of the art and future perspectives. Hepatobiliary Surg Nutr. 2016 Aug;5(4):329-44. DOI:10.21037/hbsn.2015.11.03.; Wang K, Zhu H, Meng Z, Chen Z, Lin J, Shen Y, Gao H. Safety evaluation of high intensity focused ultrasound in patients with pancreatic cancer. Onkologie. 2013;36:88-92. DOI:10.1159/000348530; Sung HY, Jung SE, Cho SH, Zhou K, Han JY, Han ST, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011;40(7):1080-1086. DOI:10.1097/mpa.0b013e31821fde24; Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Vigna PD, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol. 2010 Sep;195(3):W245-52. DOI:10.2214/AJR.09.3321.; Gao HF, Wang K, Meng ZQ, Chen Z, Lin JH, Zhou ZH, et al. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology. 2013 Nov-Dec;60(128):1906-10. DOI:10.5754/hge13498; Wang K, Chen Z, Meng Z, Lin J, Zhou Z, Wang P, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia. 2011;27(2):101-7. DOI:10.3109/02656736.2010.525588.; Li PZ, Zhu SH, He W, Zhu LY, Liu SP, Liu Y, et al. High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2012;11(6):655-60. DOI:10.1016/s1499-3872(12)60241-0; Xiong LL, Hwang JH, Huang XB, Yao SS, He CJ, Ge XH, et al. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer. JOP. 2009;10(2):123-9.; Li T, Wang YN, Khokhlova TD, D’Andrea S, Starr F, Chen H, et al. Pulsed high intensity focused ultrasound (pHIFU) enhances delivery of doxorubicin in a preclinical model of pancreatic cancer. Cancer Res. 2015 Sep 15;75(18):3738-46. DOI:10.1158/00085472.CAN-15-0296; Lau PC-P, Zheng SF, Ng WT, Yu SC-H. Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: Case report and topic review. J Dig Dis. 2012 Jan;13(1):60-4. DOI:10.1111/j.1751-2980.2011.00546.x; Zhao J, Zhao F, Shi Y, Deng Y, Hu X, Shen H. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. J Cancer Res Clin Oncol. 2017 Oct;143(10):2105-2111. DOI:10.1007/s00432-017-2459-6.; Ханевич М.Д., Манихас Г.М. Криохирургия рака поджелудочной железы. СПб.: «Аграф+», 2011, 226 с.; Goel R, Anderson K, Slaton J, Schmidlin F, Vercellotti G, Belcher J, Bischof JC. Adjuvant approaches to enhance cryosurgery. J Biomech Eng. 2009 Jul;131(7):074003. DOI:10.1115/1.3156804; Rombouts SJE, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg. 2015 Feb;102(3):182-93. DOI:10.1002/bjs.9716.; Xu K, Niu L, Yang D. Cryosurgery for pancreatic cancer. Gland Surg. 2013;2:30-39. Gland Surg. 2013 Feb;2(1):30-9. DOI:10.3978/j.issn.2227-684X.2013.02.02; Niu L, Chen J, He L, Liao M, Yuan Y, Zeng J, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. 2013 Oct;42(7):11439. DOI:10.1097/MPA.0b013e3182965dde.; He L, Niu L, Korpan NN, Sumida S, Xiao Y, Li J, et al. Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer. Pancreas. 2017 Sep;46(8):967-972. DOI:10.1097/MPA.0000000000000878.; Патютко Ю.И., Подлужный Д.В., Котельников А.Г., Сагайдак И.В. Криохирургический метод в лечении больных злокачественными опухолями поджелудочной железы. РАМН, Хирургическое отделение опухолей печени и поджелудочной железы. 2005 г. / Patyutko UI, Podluzhny DV, Kotelnikov AG, Sagaydak IV. Cryosurgical method in the treat; Li J, Chen X, Yang H, Wang X, Yuan D, Zeng Y, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J. 2011 Feb;87(1024):89-95. DOI:10.1136/pgmj.2010.098350; Al-Sakere B, Andre F, Bernat C, Connault E, Opolon P, Davalos RV, et al. Tumor ablation with irreversible electroporation. PloS one. 2007;2:1135. DOI:10.1371/journal.pone.0001135; Edelblute CM, Hornef J, Burcus NI, Norman T, Beebe SJ, Schoenbach K, et al. Controllable Moderate Heating Enhances the Therapeutic Efficacy of Irreversible Electroporation for Pancreatic Cancer. Sci Rep. 2017 Sep 18;7(1):11767. DOI:10.1038/ s41598-017-12227-4.; Wendler JJ, Fischbach K, Ricke J, Jürgens J, Fischbach F, Köllermann J, et al. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol. 2016 Feb 17;81:54-64. DOI:10.12659/ PJR.896034; Martin RC. Irreversible Electroporation of Locally Advanced Pancreatic Head Adenocarcinoma. J Gastrointest Surg. 2013 Oct;17(10):1850-6. DOI:10.1007/s11605-013-2309-z; Månsson C, Bergenfeldt M, Brahmstaedt R, Karlson B-M., Nygren P, Nilsson A. Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Anticancer Res. 2014 Jan;34(1):289-93.; Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M, et al. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. DigSurg. 2015;32(2):90–97. Dig Surg. 2015;32(2):90-7. DOI:10.1159/000375323.; Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson B-M. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol. 2016 Sep;42(9):1401-6. DOI:10.1016/j.ejso.2016.01.024; Vogel JA, Rombouts SJ, van Delden OM, Dijkgraaf MG, van Gulik TM, van Hooft JE, et al. Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA): A prospective cohort study. J Cancer Res Clin Oncol. 2017 Dec;143(12):2607-2618. doi:10.1007/s00432-017-2513-4; Lin M, Liang S, Wang X, Liang Y, Zhang M, Chen J, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J Cancer Res Clin Oncol. 2017 Dec;143(12):2607-2618. DOI:10.1007/s00432-017-2513-4; Belfiore MP, Ronza FM, Romano F, PietroIanniello G, Lucia GD, Gallo C, et al. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. Int J Surg. 2015 Sep;21 Suppl 1:S34-9. DOI:10.1016/j.ijsu.2015.06.049; Деньгина Н.В., Родионов В.В. Основы лучевой терапии злокачественных новообразований: учебно-методическое пособие для врачей и студентов. Ульяновск: УлГУ, 2013. 87 с.; Zhu X, Ju X, Cao F, Fang F, Qing S, Shen Y, et al. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial. BMJ Open. 2016 Dec 1;6(12):e013220. DOI:10.1136/bmjopen-2016-013220.; Brunner T., Nestle U., Grosu A., Partridge M. SBRT in pancreatic cancer: what is the therapeutic windows? Radiother Oncol. 2015 Jan;114(1):109-16. DOI:10.1016/j.radonc.2014.10.015; Деньгина Н.В., Мозерова Е.Я. Стереотаксическая лучевая терапия и локальная гипертермия в лечении опухолей различных локализаций. Практическая онкология. 2015;16(4):162-73.; Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul;54(7):979-85. DOI:10.3109/0284186X.2015.1004367; Zhu X, Li F, Ju X, Cao F, Cao Y, Fang F, et al. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Cancer Med. 2017 Oct;6(10):2263-2270. DOI:10.1002/cam4.1164; Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, et al. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer. 2016 Jan 10;7(3):283-8. DOI:10.7150/jca.13295.; Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549-557. https://doi.org/10.1136/gut.50.4.549; Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014 Apr 2;110(7):1698-704. DOI:10.1038/bjc.2014.95; https://www.rpmj.ru/rpmj/article/view/272

Availability: https://www.rpmj.ru/rpmj/article/view/272
https://doi.org/10.17709/2409-2231-2018-5-2-10